STERISHEALTHCARE Products
Mumbai 08042755542 info@sterispharma.com
918209542042
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
Home Products TICAGRACE 90
TICAGRACE 90Ticagre
TICAGRACE 90Ticagre
COD not available
CARDIOLOGYRANGE by Ticagrelor (90mg)

TICAGRACE 90

INR 251 INR 359
You Save: INR 108 (30.08%)
Check On
Share with
Check On
Share this on :

Description

Product details

TICAGRACE 90 Ticagrelor (90mg) TICAGRACE 90 is a medication used to prevent blood clots in individuals at risk of cardiovascular events such as heart attack or stroke. It contains the active ingredient ticagrelor, a platelet aggregation inhibitor that helps to keep blood vessels open and reduce the risk of clot formation. By inhibiting platelet activity, TICAGRACE 90 lowers the chance of blockages in arteries, thus improving blood flow and reducing the likelihood of serious cardiovascular events. It is often prescribed alongside other medications and lifestyle changes to manage and prevent heart-related conditions effectively. Regular monitoring and adherence to the prescribed dosage are essential for optimal results and safety. For further information: Email: info@sterispharma.com / contact@sterispharma.com Call/WhatsApp: 7877551268, 7849827488 Order Now:

Keywords

Other Products

Related Products

ESMOSTRUM IT: Comprehensive Product Guide Product Overview ESMOSTRUM IT is an advanced pharmaceutical formulation that combines two potent active ingredients—Esomeprazole and Itopride—to provide comprehensive relief from gastrointestinal disorders. This dual-action medication represents a significant advancement in the management of acid-related digestive conditions and motility disorders. By combining a proton pump inhibitor with a prokinetic agent, ESMOSTRUM IT addresses both the underlying causes and symptomatic manifestations of various digestive ailments, offering patients a complete therapeutic solution in a single, convenient dosage form. The synergistic combination of Esomeprazole and Itopride makes ESMOSTRUM IT particularly effective for individuals suffering from gastroesophageal reflux disease (GERD), functional dyspepsia, and other conditions where both excessive acid production and impaired gastric motility contribute to discomfort and disease progression. Active Pharmaceutical Ingredients Esomeprazole Esomeprazole is the S-isomer of omeprazole and belongs to the class of medications known as proton pump inhibitors (PPIs). It works by specifically and irreversibly blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the proton pump) located in the gastric parietal cells. This mechanism effectively reduces gastric acid secretion, providing sustained relief from acid-related symptoms and allowing damaged esophageal and gastric tissue to heal. Itopride Itopride is a prokinetic agent that enhances gastrointestinal motility through a dual mechanism of action. It acts as both a dopamine D2 receptor antagonist and an acetylcholinesterase inhibitor. By blocking dopamine receptors, it removes the inhibitory effect of dopamine on gastrointestinal motility, while its acetylcholinesterase inhibition increases acetylcholine levels, further promoting coordinated gastric contractions and improved gastric emptying. Therapeutic Uses and Indications ESMOSTRUM IT is prescribed for a wide range of gastrointestinal conditions where both acid suppression and enhanced motility are therapeutically beneficial: Gastroesophageal Reflux Disease (GERD) ESMOSTRUM IT provides exceptional relief for patients suffering from GERD, a chronic condition where stomach acid frequently flows back into the esophagus. The esomeprazole component reduces acid production, while itopride improves the tone of the lower esophageal sphincter and accelerates gastric emptying, thereby reducing the frequency and severity of reflux episodes. Functional Dyspepsia For patients experiencing persistent or recurrent upper abdominal discomfort without an identifiable organic cause, ESMOSTRUM IT addresses multiple pathophysiological mechanisms. It relieves symptoms such as early satiety, postprandial fullness, epigastric pain, and bloating by normalizing gastric acid levels and improving gastric accommodation and emptying. Peptic Ulcer Disease ESMOSTRUM IT aids in the healing of gastric and duodenal ulcers by creating an optimal healing environment through sustained acid suppression. The prokinetic action of itopride helps prevent stasis of gastric contents, which can exacerbate ulcer symptoms. Non-Ulcer Dyspepsia Many patients experience dyspeptic symptoms without evidence of ulceration. ESMOSTRUM IT effectively manages these symptoms by addressing both acid hypersecretion and delayed gastric emptying, two key factors in non-ulcer dyspepsia. Gastroparesis-Related Symptoms In conditions where gastric emptying is significantly delayed, the itopride component of ESMOSTRUM IT helps restore more normal gastric motility patterns, reducing associated symptoms like nausea, vomiting, and abdominal distension. Key Benefits and Advantages Dual Mechanism of Action The primary advantage of ESMOSTRUM IT lies in its comprehensive approach to gastrointestinal health. Rather than addressing only acid production or motility in isolation, this combination therapy tackles both aspects simultaneously, providing more complete symptom relief and better therapeutic outcomes. Superior Acid Suppression Esomeprazole offers more consistent and prolonged acid suppression compared to many other acid-reducing medications. It provides sustained relief throughout the day and night, allowing patients to experience fewer breakthrough symptoms and better quality of life. Enhanced Gastric Motility The itopride component specifically targets motility issues without crossing the blood-brain barrier significantly, meaning it provides prokinetic benefits with minimal central nervous system side effects. This results in improved gastric emptying, reduced bloating, and decreased feelings of fullness after meals. Rapid Symptom Relief Many patients experience noticeable improvement in their symptoms within the first few days of treatment with ESMOSTRUM IT. The combination therapy addresses multiple symptom pathways simultaneously, leading to faster and more comprehensive relief. Improved Quality of Life By effectively managing symptoms such as heartburn, regurgitation, nausea, bloating, and early satiety, ESMOSTRUM IT significantly enhances patients' daily functioning and overall well-being. Patients report better sleep quality, improved dietary tolerance, and reduced anxiety related to their digestive symptoms. Convenient Dosing The combination of two active ingredients in a single formulation improves medication adherence by reducing pill burden. Patients appreciate the simplicity of taking one medication instead of multiple separate preparations. Mucosal Healing Properties Beyond symptom relief, ESMOSTRUM IT promotes actual healing of damaged esophageal and gastric mucosa. The reduced acid environment created by esomeprazole allows inflamed and eroded tissue to regenerate properly. Reduced Risk of Complications By effectively controlling acid reflux and improving gastric emptying, ESMOSTRUM IT helps prevent potential complications of chronic GERD, such as esophageal strictures, Barrett's esophagus, and respiratory complications from aspiration. Dosage and Administration ESMOSTRUM IT should be taken exactly as prescribed by a healthcare professional. Typically, the medication is administered orally, preferably before meals to optimize its therapeutic effects. The standard dosing regimen usually involves once or twice daily administration, though individual requirements may vary based on the severity of the condition and patient response. The medication should be swallowed whole with water and should not be crushed, chewed, or split, as this may affect the drug's release mechanism and therapeutic efficacy. Patients should maintain regular dosing schedules to ensure optimal acid suppression and motility enhancement throughout the day. Side Effects and Safety Considerations Like all medications, ESMOSTRUM IT may cause side effects in some individuals, though not everyone experiences them. Understanding potential adverse effects helps patients identify and report concerning symptoms promptly. Common Side Effects Gastrointestinal Effects: Some patients may experience diarrhea, constipation, abdominal pain, nausea, or flatulence, particularly during initial treatment. These effects are usually mild and often resolve as the body adjusts to the medication. Headache: Mild to moderate headaches occur in a small percentage of patients and typically diminish with continued use. Dizziness: Some individuals may experience lightheadedness or dizziness, particularly when standing up quickly. Dry Mouth: Reduced saliva production may occur, leading to oral dryness and discomfort. Less Common Side Effects Skin Reactions: Rash, itching, or other dermatological manifestations may develop in sensitive individuals. Sleep Disturbances: Some patients report insomnia or unusual dreams while taking the medication. Increased Prolactin Levels: Itopride may cause mild elevation in prolactin levels, though clinical manifestations are rare. Taste Alterations: Changes in taste perception or metallic taste may occur temporarily. Serious Side Effects (Rare) While uncommon, certain serious adverse effects require immediate medical attention: Severe allergic reactions including difficulty breathing, facial swelling, or severe skin reactions Severe diarrhea that persists or contains blood Irregular heartbeat or palpitations Muscle weakness or pain Seizures or tremors Signs of liver problems including jaundice, dark urine, or persistent nausea Long-Term Considerations Extended use of proton pump inhibitors like esomeprazole has been associated with certain risks that patients should discuss with their healthcare providers: Potential reduction in calcium, magnesium, and vitamin B12 absorption Slightly increased risk of bone fractures with prolonged use Possible increased susceptibility to certain gastrointestinal infections Rare cases of kidney problems Regular monitoring and periodic assessment by healthcare professionals help minimize these risks while maintaining therapeutic benefits. Precautions and Contraindications Patients should inform their healthcare provider about all existing medical conditions, particularly liver disease, kidney problems, osteoporosis, low magnesium levels, or any gastrointestinal bleeding. ESMOSTRUM IT may interact with certain medications, including blood thinners, antifungals, HIV medications, and certain antibiotics. A complete medication review ensures safe and effective therapy. Pregnant or breastfeeding women should only use ESMOSTRUM IT under strict medical supervision, as the safety profile in these populations requires careful consideration of potential risks and benefits. Lifestyle Recommendations For optimal therapeutic outcomes, patients taking ESMOSTRUM IT should complement their medication regimen with appropriate lifestyle modifications: Avoid trigger foods that exacerbate acid reflux, such as spicy foods, citrus, chocolate, caffeine, and alcohol Maintain a healthy body weight to reduce abdominal pressure Eat smaller, more frequent meals rather than large portions Avoid lying down immediately after eating; wait at least two to three hours Elevate the head of the bed if nighttime symptoms occur Quit smoking, as tobacco use significantly worsens reflux symptoms Manage stress through relaxation techniques, as stress can exacerbate digestive symptoms Conclusion ESMOSTRUM IT represents a sophisticated and effective pharmaceutical solution for individuals struggling with complex gastrointestinal disorders involving both acid hypersecretion and impaired motility. By combining the powerful acid-suppressing capabilities of esomeprazole with the prokinetic benefits of itopride, this medication offers comprehensive symptom management that addresses the multifaceted nature of digestive disorders.
View Details
Esomeprazole and Itopride

INR182

GLISITAPTIN 100 is a pharmaceutical formulation containing Sitagliptin Phosphate 100 mg as its active ingredient. This medication represents a significant advancement in the management of type 2 diabetes mellitus, offering patients an effective oral treatment option that works through an innovative mechanism of action. As part of the DPP-4 inhibitor class of antidiabetic medications, GLISITAPTIN 100 has emerged as a trusted choice for healthcare providers and patients seeking reliable glycemic control with a favorable safety profile. The brand name GLISITAPTIN 100 signifies quality, efficacy, and a commitment to helping individuals with type 2 diabetes achieve better health outcomes. Each tablet is precisely formulated to deliver the optimal therapeutic dose of sitagliptin phosphate, ensuring consistent and predictable results in blood sugar management. Understanding Sitagliptin Phosphate Sitagliptin phosphate is a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor that has revolutionized diabetes treatment since its introduction. Unlike older diabetes medications that work through insulin secretion or glucose absorption mechanisms alone, sitagliptin operates through the incretin system—a natural bodily process that regulates blood glucose levels in response to food intake. The 100 mg strength available in GLISITAPTIN 100 represents the standard therapeutic dose for most adult patients, providing optimal efficacy while maintaining an excellent safety margin. This once-daily formulation simplifies treatment regimens and promotes better adherence, which is crucial for long-term diabetes management success. How GLISITAPTIN 100 Works GLISITAPTIN 100 works through a sophisticated yet elegant mechanism that harnesses your body's natural glucose regulation system. When you eat, your intestines release hormones called incretins, specifically GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These incretins have multiple beneficial effects: they stimulate insulin secretion from the pancreas, suppress glucagon release (which reduces glucose production by the liver), and slow gastric emptying. However, these beneficial incretins are rapidly broken down by an enzyme called DPP-4, limiting their glucose-lowering effects. GLISITAPTIN 100 inhibits this DPP-4 enzyme, allowing incretins to remain active in your bloodstream for longer periods. This results in better insulin secretion when blood glucose is elevated, reduced glucagon levels, and ultimately improved blood sugar control throughout the day. Importantly, because this mechanism is glucose-dependent, GLISITAPTIN 100 primarily works when blood sugar is elevated, which significantly reduces the risk of hypoglycemia (dangerously low blood sugar) compared to some other diabetes medications. Primary Uses and Indications Type 2 Diabetes Mellitus Management: GLISITAPTIN 100 is primarily indicated for improving glycemic control in adult patients with type 2 diabetes mellitus. It can be prescribed as: Monotherapy: As a first-line treatment for patients who cannot achieve adequate control through diet and exercise alone, particularly when metformin is contraindicated or not tolerated Combination Therapy: Alongside metformin, sulfonylureas, thiazolidinediones, or insulin when these medications alone do not provide sufficient glucose control Triple Therapy: In combination with two other antidiabetic agents when dual therapy fails to achieve target HbA1c levels The medication is particularly suitable for patients who require effective glucose control but have concerns about weight gain or hypoglycemia, as GLISITAPTIN 100 is weight-neutral and has a low hypoglycemia risk when used as monotherapy. Key Benefits of GLISITAPTIN 100 1. Effective Glycemic Control Clinical studies have demonstrated that GLISITAPTIN 100 significantly reduces HbA1c levels (a measure of long-term blood sugar control) by approximately 0.5-1.0%, helping patients achieve and maintain target glucose levels. This improvement translates to reduced risk of diabetes-related complications over time. 2. Low Hypoglycemia Risk Unlike sulfonylureas or insulin, GLISITAPTIN 100 has a glucose-dependent mechanism, meaning it primarily works when blood sugar is elevated. This dramatically reduces the risk of hypoglycemic episodes, providing patients with greater safety and peace of mind, especially important for elderly patients or those with unpredictable meal schedules. 3. Weight Neutral GLISITAPTIN 100 does not cause weight gain, a significant advantage over some other diabetes medications like insulin, sulfonylureas, or thiazolidinediones. Maintaining a healthy body weight is crucial for overall diabetes management and cardiovascular health. 4. Once-Daily Convenience The single daily dose requirement of GLISITAPTIN 100 simplifies treatment regimens, making it easier for patients to maintain adherence. Better adherence directly correlates with improved glycemic control and better long-term outcomes. 5. Pancreatic Preservation By working through the incretin system, GLISITAPTIN 100 may help preserve pancreatic beta-cell function, potentially slowing the progression of type 2 diabetes. This represents a significant long-term benefit beyond simple glucose control. 6. Cardiovascular Safety Clinical trials have demonstrated cardiovascular safety with sitagliptin, an important consideration given that cardiovascular disease is the leading cause of morbidity and mortality in patients with type 2 diabetes. 7. Renal Dosing Available While the 100 mg dose is standard, sitagliptin can be adjusted for patients with kidney impairment, making it accessible to a broader patient population, including those with diabetic nephropathy. 8. Well-Tolerated GLISITAPTIN 100 generally has a favorable side effect profile, with most patients experiencing minimal adverse effects, contributing to better quality of life during treatment. Dosage and Administration The standard recommended dose of GLISITAPTIN 100 is one tablet taken orally once daily, with or without food. The medication can be taken at any time of day, though taking it at the same time daily helps establish a routine and ensures consistent blood levels. For patients with moderate to severe kidney disease, dosage adjustments may be necessary. Your healthcare provider will determine the appropriate dose based on your kidney function tests. It's crucial to follow your doctor's instructions precisely and not adjust your dose without medical guidance. Potential Side Effects While GLISITAPTIN 100 is generally well-tolerated, like all medications, it may cause side effects in some individuals: Common Side Effects (Affecting 1-10% of patients): Upper respiratory tract infections Nasopharyngitis (common cold symptoms) Headache Nausea Abdominal pain Diarrhea These side effects are typically mild and often resolve on their own as your body adjusts to the medication. Less Common but Serious Side Effects: Pancreatitis: Severe abdominal pain that may radiate to the back, with or without vomiting, requires immediate medical attention Severe Joint Pain: Persistent, severe joint pain has been reported in some patients; inform your doctor if this occurs Allergic Reactions: Rare cases of serious allergic reactions including anaphylaxis, angioedema, and severe skin reactions have occurred Heart Failure: In patients with existing heart disease, worsening heart failure has been reported Bullous Pemphigoid: A rare skin condition requiring discontinuation of the medication When Used with Other Diabetes Medications: When GLISITAPTIN 100 is combined with sulfonylureas or insulin, the risk of hypoglycemia increases. Your doctor may reduce the dose of these medications when adding GLISITAPTIN 100 to your regimen. Precautions and Contraindications Do Not Use GLISITAPTIN 100 if: You are allergic to sitagliptin or any ingredients in the formulation You have type 1 diabetes or diabetic ketoacidosis You are under 18 years of age (safety and efficacy not established) Use with Caution if: You have a history of pancreatitis You have kidney disease (dose adjustment required) You have heart failure You are pregnant or planning to become pregnant You are breastfeeding Important Patient Information Monitoring: Regular monitoring of blood glucose levels and HbA1c testing (typically every 3-6 months) is essential to assess treatment effectiveness and make necessary adjustments. Lifestyle Factors: GLISITAPTIN 100 works best when combined with a healthy diet, regular physical activity, and weight management. Medication alone cannot substitute for comprehensive lifestyle management. Missed Dose: If you miss a dose, take it as soon as you remember on the same day. If it's almost time for your next dose, skip the missed dose and continue with your regular schedule. Never double up doses. Storage: Store GLISITAPTIN 100 at room temperature, away from moisture and heat. Keep the medication in its original container and out of reach of children. Drug Interactions GLISITAPTIN 100 has few significant drug interactions, contributing to its safety profile. However, inform your healthcare provider about all medications, supplements, and herbal products you're taking. Particular attention should be paid to: Other diabetes medications (may require dose adjustments) Digoxin (levels may be slightly increased) Medications affecting kidney function Conclusion GLISITAPTIN 100 (Sitagliptin Phosphate 100 mg) represents a modern, effective, and well-tolerated option for managing type 2 diabetes mellitus. Its innovative mechanism through the incretin system offers multiple advantages including effective glucose control, low hypoglycemia risk, weight neutrality, and once-daily convenience. These benefits make it an excellent choice for many patients, whether used alone or in combination with other antidiabetic medications.
View Details
Sitagliptin Phosphate 100 mg

INR464

CLANARIZINE DOM represents an advanced pharmaceutical combination that brings together two potent therapeutic agents—Cinnarizine and Domperidone—in a single convenient tablet formulation. This innovative combination medication addresses multiple aspects of vestibular disorders, motion sickness, and associated nausea and vomiting, providing comprehensive relief for patients suffering from these debilitating conditions. Manufactured under stringent quality control standards, CLANARIZINE DOM offers a synergistic approach to managing symptoms that significantly impact quality of life and daily functioning.The combination of Cinnarizine and Domperidone in CLANARIZINE DOM is based on sound pharmacological principles. While Cinnarizine works primarily on the vestibular system to reduce dizziness and vertigo, Domperidone acts as an effective antiemetic to control nausea and vomiting. Together, these two active ingredients provide more comprehensive symptom control than either agent alone, making CLANARIZINE DOM an excellent choice for patients experiencing vestibular disturbances accompanied by gastrointestinal symptoms.This combination therapy is particularly valuable because vertigo, dizziness, and motion sickness are frequently accompanied by nausea and vomiting. Patients suffering from these conditions often find that addressing only one aspect of their symptoms provides insufficient relief. CLANARIZINE DOM's dual-action formula tackles both the underlying vestibular dysfunction and the accompanying gastrointestinal distress, offering patients a more complete therapeutic solution that improves both comfort and functional capacity.Understanding the Active IngredientsCinnarizine is a calcium channel blocker with specific antihistaminic and vestibular suppressant properties. Unlike systemic calcium channel blockers used for cardiovascular conditions, Cinnarizine selectively acts on the blood vessels in the inner ear and brain, improving blood flow to these areas. This enhanced circulation helps reduce the frequency and severity of vertigo attacks while also preventing motion sickness. Cinnarizine also possesses mild antihistaminic effects that contribute to its anti-nausea properties, though this is not its primary mechanism of action.The medication works by blocking calcium channels in the vestibular system, which helps stabilize the sensory organs responsible for balance. By reducing the excessive stimulation of the vestibular apparatus, Cinnarizine decreases the sensation of spinning or imbalance that characterizes vertigo. Additionally, its vasodilatory effects improve microcirculation in the inner ear, which can be beneficial for conditions where reduced blood flow contributes to symptoms.Domperidone is a peripheral dopamine antagonist that acts primarily as a prokinetic and antiemetic agent. Unlike some antiemetic medications that cross the blood-brain barrier and cause sedation or extrapyramidal side effects, Domperidone works predominantly in the peripheral nervous system. It blocks dopamine receptors in the chemoreceptor trigger zone (CTZ) located outside the blood-brain barrier, effectively preventing nausea and vomiting without causing significant central nervous system effects.Domperidone also enhances gastrointestinal motility by promoting coordinated contractions of the stomach and upper small intestine. This prokinetic effect helps empty the stomach more efficiently, reducing feelings of fullness, bloating, and discomfort that often accompany vestibular disorders. By accelerating gastric emptying, Domperidone also reduces the likelihood of gastroesophageal reflux, which can exacerbate nausea in some patients.The combination of these two medications in CLANARIZINE DOM creates a complementary therapeutic effect. While Cinnarizine addresses the vestibular component of dizziness and vertigo, Domperidone manages the gastrointestinal symptoms that frequently accompany these conditions. This dual approach provides more comprehensive symptom relief and improves overall treatment outcomes compared to monotherapy with either agent alone.Clinical Applications and UsesCLANARIZINE DOM is indicated for a wide range of conditions characterized by vertigo, dizziness, and associated nausea. Understanding these clinical applications helps healthcare providers select appropriate candidates for this combination therapy.Vestibular Disorders: The primary indication for CLANARIZINE DOM includes various vestibular disorders that cause vertigo and imbalance. These conditions include Ménière's disease, benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and labyrinthitis. Patients with these disorders experience episodes of spinning sensation, loss of balance, and often severe nausea. CLANARIZINE DOM helps reduce the frequency and intensity of vertigo attacks while controlling the accompanying gastrointestinal symptoms.Motion Sickness: CLANARIZINE DOM is highly effective for preventing and treating motion sickness, whether related to travel by car, boat, airplane, or amusement park rides. The medication can be taken prophylactically before travel or at the onset of symptoms. The combination is particularly useful for individuals who experience severe nausea and vomiting with motion sickness, as Domperidone provides powerful antiemetic effects that complement Cinnarizine's anti-motion-sickness properties.Migraine-Associated Vertigo: Many patients with migraines experience vestibular symptoms, including dizziness, vertigo, and motion sensitivity, either during migraine attacks or as independent episodes. CLANARIZINE DOM can help manage these vestibular manifestations of migraine, reducing both the vertigo and the nausea that often accompany migraine headaches.Post-Concussion Syndrome: Following head injuries, some patients develop persistent dizziness, balance problems, and nausea as part of post-concussion syndrome. CLANARIZINE DOM may provide symptomatic relief for these patients during their recovery period, though it should be used as part of a comprehensive treatment approach that includes rest, gradual return to activities, and vestibular rehabilitation when appropriate.Cerebrovascular Insufficiency: In older adults with reduced blood flow to the brain, symptoms such as dizziness, vertigo, tinnitus (ringing in the ears), and cognitive difficulties may develop. Cinnarizine's vasodilatory properties can improve cerebral circulation, potentially reducing these symptoms. The addition of Domperidone helps manage any associated nausea.Radiation-Induced or Chemotherapy-Induced Nausea: While not a primary indication, some healthcare providers use CLANARIZINE DOM as adjunctive therapy for patients undergoing cancer treatment who experience both nausea and dizziness. Domperidone's strong antiemetic properties are particularly valuable in this context.Key Benefits of CLANARIZINE DOMThe unique combination of Cinnarizine and Domperidone in CLANARIZINE DOM offers numerous advantages that make it a preferred choice for managing vestibular disorders and associated symptoms.Comprehensive Symptom Control: The primary benefit of CLANARIZINE DOM is its ability to address multiple symptoms simultaneously. Rather than requiring patients to take separate medications for vertigo and nausea, this combination provides unified treatment in a single tablet. This comprehensive approach improves symptom control across the full spectrum of vestibular disorder manifestations, from the spinning sensation to the gastrointestinal distress that often accompanies it.Improved Patient Compliance: Taking multiple medications can be burdensome, particularly for patients who feel dizzy or nauseated. CLANARIZINE DOM simplifies the treatment regimen by combining two medications in one tablet, making it easier for patients to adhere to their prescribed therapy. Better compliance translates to better outcomes, as consistent medication use is essential for managing chronic vestibular conditions.Synergistic Therapeutic Effects: The combination of Cinnarizine and Domperidone creates synergistic effects that enhance overall efficacy. While Cinnarizine reduces vestibular stimulation and improves inner ear blood flow, Domperidone prevents nausea and promotes gastric emptying. This dual action addresses both the cause and consequences of vestibular dysfunction, providing more complete relief than either medication alone.Reduced Central Nervous System Side Effects: Because Domperidone works primarily in the peripheral nervous system rather than crossing the blood-brain barrier extensively, CLANARIZINE DOM causes less sedation and fewer cognitive effects compared to some alternative antiemetic medications. This allows patients to maintain better alertness and function during treatment, which is particularly important for those who need to continue working or performing daily activities.Enhanced Quality of Life: Vertigo and chronic dizziness significantly impair quality of life, limiting mobility, social interactions, and occupational functioning. The nausea and vomiting that accompany these conditions add another layer of disability. By effectively controlling both vestibular and gastrointestinal symptoms, CLANARIZINE DOM helps restore patients' ability to engage in normal activities, improving overall life satisfaction and functional independence.Fast Onset of Action: CLANARIZINE DOM provides relatively rapid symptom relief, with many patients experiencing improvement within 30 minutes to 2 hours after taking the medication. This quick onset is particularly valuable for acute episodes of vertigo or when taking the medication prophylactically before situations that might trigger motion sickness.Suitable for Long-Term Use: For patients with chronic vestibular disorders requiring ongoing treatment, CLANARIZINE DOM is generally safe for extended use when properly monitored by a healthcare provider. The medication maintains its effectiveness over time without significant tolerance development, making it suitable for long-term symptom management.Improved Gastric Emptying: The prokinetic effects of Domperidone benefit not only nausea but also other gastrointestinal symptoms such as early satiety, bloating, and upper abdominal discomfort. Patients with vestibular disorders often develop gastroparesis or delayed gastric emptying secondary to their condition, and Domperidone addresses this issue effectively.Vascular Benefits: Cinnarizine's ability to improve blood flow to the inner ear and brain provides additional benefits beyond symptom control. Enhanced microcirculation may support healing and recovery in conditions where vascular insufficiency contributes to vestibular dysfunction.Side Effects and Safety ConsiderationsLike all medications, CLANARIZINE DOM can cause side effects, though not everyone experiences them. Understanding potential adverse effects helps patients recognize when to seek medical attention and allows healthcare providers to monitor therapy appropriately.Common Side Effects:The most frequently reported side effect of CLANARIZINE DOM is drowsiness or sedation, occurring in approximately 10-20% of patients. This effect is primarily attributable to Cinnarizine's antihistaminic properties. Patients should avoid driving or operating machinery until they know how the medication affects them. Taking the medication at bedtime can minimize daytime drowsiness for some patients.Dry mouth is another common side effect, affecting roughly 10-15% of patients. This occurs due to anticholinergic effects and can be managed by sipping water frequently, chewing sugar-free gum, or using saliva substitutes if severe. Maintaining good oral hygiene is important to prevent dental problems associated with reduced saliva production.Mild gastrointestinal symptoms, including constipation, abdominal discomfort, or changes in bowel habits, may occur. While Domperidone promotes gastric emptying, it can occasionally alter bowel motility. These effects are usually mild and resolve with continued use or dose adjustment.
View Details
Cinnarizine and Domperidone Tablets

INR55

Have any question or need any business consultation?

Contact Us

Have any question or need any business consultation?

Contact Us
Chat with us